UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

Haematologica (Roma), 2020-09, Vol.105 (9), p.2190-2191

Silver, Richard T

2020

Volltextzugriff (PDF)

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.799-807

2012

Volltextzugriff (PDF)

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Journal of clinical oncology, 2009-12, Vol.27 (35), p.6041-6051

2009

Volltextzugriff (PDF)

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Journal of clinical oncology, 2011-02, Vol.29 (6), p.761-770

2011

Volltextzugriff (PDF)

Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival

Leukemia, 2023-03, Vol.37 (3), p.691-694

2023

Volltextzugriff (PDF)

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Journal of hematology and oncology, 2017-02, Vol.10 (1), p.55-14, Article 55

2017

Volltextzugriff (PDF)

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis

Blood, 2013-09, Vol.122 (11), p.1881-1886

2013

Volltextzugriff (PDF)

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal

Blood, 2008-07, Vol.112 (2), p.231-239

2008

Volltextzugriff (PDF)

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

JNCI : Journal of the National Cancer Institute, 2016-07, Vol.108 (7), p.djw003

2016

Volltextzugriff (PDF)

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

Journal of clinical oncology, 2013-04, Vol.31 (10), p.1285-1292

2013

Volltextzugriff (PDF)

New Perspectives of Interferon‐alpha2 and Inflammation in Treating Philadelphia‐negative Chronic Myeloproliferative Neoplasms

HemaSphere, 2021-12, Vol.5 (12), p.e645-n/a

2021

Volltextzugriff (PDF)

Management of CML-blast crisis

Best practice & research. Clinical haematology, 2016-09, Vol.29 (3), p.295-307

2016

Volltextzugriff (PDF)

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

Nature genetics, 2009-04, Vol.41 (4), p.446-449

2009

Volltextzugriff (PDF)

In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice

American journal of physiology. Heart and circulatory physiology, 2012-04, Vol.302 (7), p.H1367-H1377

2012

Volltextzugriff (PDF)

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Blood, 2007-03, Vol.109 (6), p.2303-2309

2007

Volltextzugriff (PDF)

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

Journal of clinical oncology, 2008-07, Vol.26 (19), p.3204-3212

2008

Volltextzugriff (PDF)

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

Haematologica (Roma), 2022-11, Vol.107 (11), p.2641-2649

2022

Volltextzugriff (PDF)

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Haematologica (Roma), 2010-02, Vol.95 (2), p.232-240

2010

Volltextzugriff (PDF)

Are thrombosis, progression, and survival in ET predictable?

Blood cancer journal (New York), 2024-06, Vol.14 (1), p.103-3, Article 103

2024

Volltextzugriff (PDF)

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients

Haematologica (Roma), 2017-03, Vol.102 (3), p.e97-e99

2017

Volltextzugriff (PDF)

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

BMC cancer, 2018-04, Vol.18 (1), p.359-359, Article 359

2018

Volltextzugriff (PDF)

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

Blood, 2010-06, Vol.115 (22), p.4517-4523

2010

Volltextzugriff (PDF)

1 – 25 von 1.977

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.634)
Mit Volltextzugriff
(1.518)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(1.049)
Journals@Ovid Ovid Full Text
(837)
EZB Electronic Journals Library
(815)
NUS Single-Journal Subscriptions
(766)
Ingenta
(711)
Elsevier ScienceDirect Journals Complete
(414)
IngentaConnect Journals
(279)
Wiley Blackwell Single Titles
(235)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(208)
Wiley Online Library
(183)
JSTOR
(89)
Springer Journals
(86)
Taylor & Francis
(65)
Nexis Uni
(62)
Taylor & Francis Online
(58)
Oxford Journals
(56)
SAGE Publications
(54)
Taylor & Francis Journals
(54)
SpringerLINK Contemporary (Konsortium Baden-Württemberg)
(50)
Business Source Ultimate
(50)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet

Splenomegaly (SPML) in polycythemia vera (PV): its clinical significance and its relation to symptoms, post-polycythemic myelofibrosis (PPMF) and survival

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial

Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis

The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial

New Perspectives of Interferon‐alpha2 and Inflammation in Treating Philadelphia‐negative Chronic Myeloproliferative Neoplasms

Management of CML-blast crisis

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

In vivo two-photon excited fluorescence microscopy reveals cardiac- and respiration-dependent pulsatile blood flow in cortical blood vessels in mice

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Are thrombosis, progression, and survival in ET predictable?

Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project

Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patients

Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)

The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms

Suchergebnisse filtern